Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 1/2017

Open Access 01-12-2017 | Review

Neuropathic Pain and Sleep: A Review

Author: Luigi Ferini-Strambi

Published in: Pain and Therapy | Special Issue 1/2017

Login to get access

Abstract

Neuropathic pain is associated with sleep disturbances, and in turn poor sleep quality leads to increased pain sensitivity, so it is essential to assess sleep alongside neuropathic pain. Responses to drugs are inconsistent and identifying the best treatment option that will reduce pain and improve sleep quality remains challenging for clinicians. Anticonvulsants such as pregabalin and gabapentin improve neuropathic pain and have a positive effect on comorbid sleep disturbances. Opioids and antidepressants are effective in reducing pain but can exacerbate sleep disturbances.
Funding: Pfizer, Italy.
Literature
1.
Cheatle MD, Foster S, Pinkett A, Lesneski M, Qu D, Dhingra L. Assessing and managing sleep disturbance in patients with chronic pain. Anesthesiol Clin. 2016;34(2):379–93.CrossRefPubMed
2.
Institute of Medicine (US) Committee on Sleep Medicine and Research. Sleep physiology. In: Colten HR, Altevogt BM, editors. Sleep disorders and sleep deprivation: an unmet public health problem. Washington, DC: The National Academies Press; 2006.
3.
Almoznino G, Benoliel R, Sharav Y, Haviv Y. Sleep disorders and chronic craniofacial pain: characteristics and management possibilities. Sleep Med Rev. 2017;33:39–50.CrossRefPubMed
4.
Lampl C, Schweiger C, Haider B, Lechner A. Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. J Neurol. 2010;257(8):1265–73.CrossRefPubMed
5.
Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin. 2010;26(10):2411–9.CrossRefPubMed
6.
Benoliel R, Eliav E, Sharav Y. Self-reports of pain-related awakenings in persistent orofacial pain patients. J Orofac Pain. 2009;23(4):330–8.PubMed
7.
Devor M, Wood I, Sharav Y, Zakrzewska JM. Trigeminal neuralgia during sleep. Pain Pract. 2008;8(4):263–8.CrossRefPubMed
8.
Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab. 2010;95(11):4802–11.CrossRefPubMed
9.
Mehta N, Bucior I, Bujanover S, Shah R, Gulati A. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes. 2016;14:54.CrossRefPubMedPubMedCentral
10.
Sivertsen B, Lallukka T, Petrie KJ, Steingrimsdottir OA, Stubhaug A, Nielsen CS. Sleep and pain sensitivity in adults. Pain. 2015;156(8):1433–9.CrossRefPubMed
11.
D’Angelo R, Morreale A, Donadio V, et al. Neuropathic pain following spinal cord injury: what we know about mechanisms, assessment and management. Eur Rev Med Pharmacol Sci. 2013;17(23):3257–61.PubMed
12.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.CrossRefPubMed
13.
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.CrossRefPubMedPubMedCentral
14.
Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23(1):15–22.CrossRefPubMed
15.
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831–6.CrossRefPubMed
16.
Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109(1–2):26–35.CrossRefPubMed
17.
Freynhagen R, Grond S, Schupfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract. 2007;61(12):1989–96.CrossRefPubMed
18.
Markman JD, Jensen TS, Semel D, et al. Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials. Pain Pract. 2017;17(6):718–28.CrossRefPubMed
19.
Fan H, Yu W, Zhang Q, et al. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2014;39(4):334–42.CrossRefPubMed
20.
Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2014;80(5):556–67.PubMed
21.
McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26(10):883–92.CrossRefPubMed
22.
Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015;20(2):107–14.CrossRef
23.
Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology. 2013;98(4):267–80.CrossRefPubMed
24.
Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758–65.CrossRefPubMedPubMedCentral
25.
Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20(5):1226–40.
26.
Correa D, Farney RJ, Chung F, Prasad A, Lam D, Wong J. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015;120(6):1273–85.CrossRefPubMed
27.
Hassamal S, Miotto K, Wang T, Saxon AJ. A narrative review: the effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. Am J Addict. 2016;25(6):452–65.CrossRefPubMed
28.
Trenkwalder C, Zieglgänsberger W, Ahmedzai SH, Högl B. Pain, opioids, and sleep: implications for restless legs syndrome treatment. Sleep Med. 2017;31:78–85.CrossRefPubMed
29.
Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90(4):532–45.CrossRefPubMed
30.
Bliwise DL, Zhang RH, Kutner NG. Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS). Sleep Med. 2014;15(10):1241–5.CrossRefPubMedPubMedCentral
31.
Bazil CW, Dave J, Cole J, Stalvey J, Drake E. Pregabalin increases slow-wave sleep and may improve attention in patients with partial epilepsy and insomnia. Epilepsy Behav. 2012;23(4):422–5.CrossRefPubMed
32.
Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia. 2014;55(1):26–37.CrossRefPubMed
33.
Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23.CrossRefPubMed
34.
Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18(36):5802–17.CrossRefPubMed
35.
Metadata
Title
Neuropathic Pain and Sleep: A Review
Author
Luigi Ferini-Strambi
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue Special Issue 1/2017
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-017-0089-y

Other articles of this Special Issue 1/2017

Pain and Therapy 1/2017 Go to the issue

Review

Pharmacotherapy for Neuropathic Pain: A Review

Review

A Review of Neuropathic Pain: From Diagnostic Tests to Mechanisms

Review

A Review of the Emotional Aspects of Neuropathic Pain: From Comorbidity to Co-Pathogenesis

Review

A review of Neuropathic Pain: From Guidelines to Clinical Practice

Editorial

Neuropathic Pain: The Scope of the Problem
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits